HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a definitive agreement to acquire Dura Medical, a revenue-generating and EBITDA-positive interventional psychiatry clinic on Florida's west coast. This acquisition, combined with the previously announced Neurospa TMS network, will expand HOPE's comprehensive mental health services in Florida.
Dura Medical, founded in 2018, specializes in treating mental health and chronic pain using advanced interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato®, and Stellate Ganglion Blocks. The clinic serves both civilian and veteran patients through the Veterans Affairs Community Cares Network.
Stephen Durand, Dura's founder and a US Army Reserve Veteran, will serve as Director of Florida Clinic Operations for HOPE. Dura Medical aims to treat more than 10,000 people by 2026. The acquisition's closing is pending financial audits, regulatory approvals, and standard closing conditions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.